Previous 10 | Next 10 |
Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, announced today that the U.S. Food and Drug Administration (FDA) has cleared Legend Biotech’...
Seven accepted poster presentations showcase our continued leadership in CAR-T cell therapy research for patients with multiple myeloma New analysis of sustained minimal residual disease (MRD) negativity from the pivotal CARTITUDE-1 study of CARVYKTI ® (ciltacab...
Summary Legend Bio's Carvykti has been approved and is selling well despite manufacturing issues. Analysts have set multibillion-dollar target peak sales for the product. To realize these, approval in only fifth-line multiple myeloma is not enough. Legend Biotech Cor...
Summary Legend Biotech's Carvykti was approved this year for the treatment of fourth and fifth-line-plus multiple myeloma. Carvykti is partnered with J&J, and the launch is off to a strong start despite supply challenges, thanks to the outstanding CARTITUDE-1 trial data. L...
Legend Biotech (NASDAQ: LEGN) , a commercial-stage Chinese biotech company that specializes in oncology and cell therapies, saw its shares rise 14.2% on Tuesday. The stock closed on Monday at $40.20, then opened on Tuesday at $41.44. It rose to a high of $46.53 after lunch before cl...
Legend Biotech Corporation ( NASDAQ: LEGN ), a company focused on cell therapies, traded sharply higher on Tuesday as Wall Street used Q3 2022 results from Johnson & Johnson ( JNJ ) to estimate sales of multiple myeloma therapy Carvykti for which the two have partnered...
Japan's Ministry of Health, Labour and Welfare has approved Legend Biotech's ( NASDAQ: LEGN ) Carvykti (ciltacabtagene autoleucel) for relapsed/refractory multiple myeloma. The New Drug Application in the country was submitted by Legend's ( LEGN ) pa...
Legend Biotech Corporation (NASDAQ: LEGN), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved CARVYKTI ™ ...
Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today announced it will host its in-person and virtual Research & Development Day on Monday, O...
Summary According to a Wall Street Journal report, China and the US are close to solving the accounting rules crisis that threatens to de-list 261 China companies from US exchanges. Lee's Pharm of Hong Kong entered a $78.9 million deal with Windtree Therapeutics for global rights ...
News, Short Squeeze, Breakout and More Instantly...
Legend Biotech Corporation Company Name:
LEGN Stock Symbol:
NASDAQ Market:
Legend Biotech Corporation Website:
SOMERSET, N.J., July 10, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am ET on Friday, August 9, 2024, to review second-quarter 2024 results. During the webcast and confe...
SOMERSET, N.J., July 02, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, announced today positive overall survival results from CARTITUDE-4, an ongoing, global randomized, open-label Phase 3 study evaluating the efficacy and sa...
2024-06-20 17:01:11 ET USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – June 20,2024 – USA News Group News Commentary – The potential threat of cancer looms for everyone, but now new studies are revealing an increased number o...